INTRODUCTION
PTCH1 is a tumour suppressor gene underlying the nevoid BCC (basal cell carcinoma) syndrome, an autosomal dominant disorder characterized by multiple developmental abnormalities and predisposition to BCC and other tumours [1, 2] . In the non-signalling state, PTCH1 is thought to inhibit the constitutive signalling of another membrane protein SMO (Smoothened). Binding of SHH (Sonic Hedgehog) to PTCH1 releases this inhibition allowing signalling to be transduced to a microtubuleassociated complex. This complex is best characterized in Drosophila and contains a number of intracellular components including costal2, a protein with kinesin-like motif, the serine/ threonine kinase fused, suppressor-of-fused and the zinc-fingercontaining transcription factor Cubitus interuptus (ci). Furthermore, dispatched and tout-velu are two proteins involved in modulating hh (Hedgehog) signalling in secreting and receiving cells respectively [3, 4] .
The hh family includes secreted proteins that undergo autocatalytic cleavage and modification to give a 20 kDa, active N-terminal fragment covalently bound to cholesterol [5] and palmitic acid [6] . Mammals have three different types of HH proteins, SHH, Indian HH and DHH (Desert HH), two patched receptors, PTCH1 and PTCH2 and three ci-like proteins, GLI1, GLI2 and GLI3 [7] . In addition, mammals have a HH-interacting protein, not found in Drosophila, which appears to function as a regulator of ligand availability [8] . Moreover, different isoforms of several key components in this pathway have been observed in mammals. For example, expression of alternative first exons Abbreviations used: BCC, basal cell carcinoma; HA, haemagglutinin; HH, Hedgehog; DHH, Desert HH; SHH, Sonic HH; HEK-293, human embryonic kidney 293 cells; SMO, Smoothened; SSD, sterol-sensing domain. 1 Correspondence may be addressed to either author (e-mail rune.toftgard@cnt.ki.se or peter.zaphiropoulos@cnt.ki.se).
of the human PTCH1 gene is differentially regulated in normal tissues and tumours, with the alternative first exon, exon 1B, being required for full inhibition of SMO signalling [9] . On the other hand, deletion of the last 156 amino acids of Drosophila ptch ectopically activates the hh pathway, suggesting that these amino acids are required to repress signalling in the fly [10] . Finally, expression of three different 5 -untranslated regions in GLI1 mRNAs transcripts has been observed in mouse and human tissues. Post-transcriptional regulation of GLI1 appears to be mediated by exon skipping of these untranslated exons and an association of the most efficiently translated GLI1 mRNA with BCC has been observed [11] . The second to sixth transmembrane domains of PTCH1 show high similarity to the cholesterol-sensing motif of the NiemannPick disease protein and 3-hydroxy-3-methylglutaryl-CoA reductase [12, 13] . The function of this similar domain is not known and so far there is no evidence that PTCH1 participates in cholesterol homoeostasis, but this motif may have a role in modulating signalling. Drosophila ptch with mutations in this SSD (sterolsensing domain) acts in a dominant-negative pattern, causing derepression of hh target genes. This is in spite of the fact that the mutants are able to bind hh [14, 15] . However, similar mutations in this region in mouse Ptch1 did not yield comparable results, highlighting functional differences between vertebrates and flies [16] .
PTCH2, a gene similar to PTCH1, was identified in our laboratory and localized to the short arm of chromosome 1(1p32.1-32.3) [17] . PTCH2 comprises 23 coding exons and spans approx. 15 kb of genomic DNA. The gene encodes a 1203 amino acid [18, 19] . The physiological function of PTCH2 is still unknown. Most experiments have been focused on PTCH1 but it is known that Ptch1 and Ptch2 are differentially expressed in mouse during epidermal development [20] . Tissue distribution analysis indicates that PTCH2 is preferentially expressed in skin and testis. Binding analysis shows that both PTCH1 and PTCH2 can interact with all HH family members with similar affinity and form a complex with SMO [21] . Suppression of hair follicle development inhibits induction of Shh, Ptch1 and Ptch2 in hair germs in mice [22] . Thus PTCH2 appears to be involved in SHH/PTCH cell signalling. However, PTCH2 mutations are very rare events in medulloblastomas and BCCs [23] . Moreover, the fact that the mutated PTCH1 in BCCs cannot be replaced by overexpressed PTCH2 implies that PTCH2 has related, but yet distinct functions when compared with PTCH1 [17] .
In this study, we analysed the functional properties of three PTCH2 splice variants in relation to PTCH1 within the context of the HH signalling pathway. Differences in the ability to modulate signalling were revealed among these isoforms of PTCH2. However, PTCH1 was consistently characterized by a stronger inhibitory activity when compared with any of the PTCH2 variants.
MATERIALS AND METHODS

Tissue distribution analysis
The multiple tissue cDNA (MTC TM ) panel from ClonTech Laboratories (Palo Alto, CA, U.S.A.), cerebellum cDNA (ClonTech Laboratories) and skin cDNA, as described before [9] , were used to detect PTCH2 splice variants by PCR. The primers were obtained from Cybergene AB (Huddinge, Sweden) ( Table 1) . Each reaction consisted of 5 µl of 10× buffer B (Promega, Madison, WI, U.S.A.), 8 µl of dNTP mixture (1.25 mM each), the required amount of each primer to reach 0.5-1.0 mM, 1.0 µl of Taq DNA polymerase (5 units/µl), 4 µl of MgCl 2 (25 mM) and 5 µl of cDNA in a total volume of 50 µl. Thirty cycles with 1 min at 95
• C, 1 min at 54 • C and 1 min at 72
• C were performed on a PerkinElmer thermocycler. For nested PCR, 0.5 µl of the initial amplification products was used. Amplifications without exogenous cDNA were used in all sets of experiments as a negative control. The nested products were analysed on a 4 % NuSieve 3:1 agarose gel (FMC BioProducts, Rockland, ME, U.S.A.). All PCR products were cloned and sequence-verified (Cybergene AB).
Expression constructs
Overlap PCR was used to generate constructs for the full-length cDNA of PTCH2 and the observed splice variants. Different clones obtained by 5 -RACE (rapid amplification of cDNA ends)-PCR in combination with the 3 -end of the Incyte PTCH2 clones [17] were therefore used with the Advantage HF TM PCR kit (ClonTech Laboratories). Three constructs were made. The fulllength PTCH2 that included exons 20, 21 and 22 (PTCH2), PTCH2-22 that has the last exon substituted by 'intronic' sequence and PTCH2-9,10 that lacks exons 9 and 10. We chose to use the 3 -end region present in PTCH2-22 for this last construct because of the detection of that 3 -end transcript in all tissues examined. The amplified cDNAs for each construct were inserted into the pcDNA3.1/His B (Invitrogen, Carlsbad, CA, U.S.A.) mammalian expression vector. The primer sequences used for overlap PCR are available on request.
A full-length 3 -FLAG tagged PTCH1 construct with the alternative first exon, exon 1B [9] , was used. The insert was also subcloned into pcDNA3.1/His A (Invitrogen) to generate PTCH1/ PTCH2 expression constructs with the same vector backbone.
A cDNA construct containing the human N-terminal DHH cDNA was generated from testis RNA as follows: a mixture of 4 µl of MgCl 2 (25 mM), 2 µl of reverse transcription 10× buffer (Promega), 2 µl of dNTP mixture (10 mM), 0.5 µl of recombinant RNasin ® RNase inhibitor, 0.75 µl of avian myeloblastosis virus reverse transcriptase (15 units), 1 µl of DHHspecific primer (5 -AGGCGCACAGTTGCA) (0.5 µg) and 10 µg of total RNA was incubated for 60 min at 42
• C. The singlestranded cDNA was subsequently used for PCR to amplify a region of approx. 600 bp in DHH, which corresponds to that of the SHH expression construct (see below). The forward primer 5 -GCGGTACCATGGCTCTCCTGACCAATC and the reverse primer 5 -GCGAAGCTTTTTCCCGGAAAGCAGCCG were flanked by KpnI and HindIII sequences. The PCR fragment was cloned into KpnI-HindIII-digested CMV5 vector. All constructs were verified by sequencing (Cybergene AB).
Other expression constructs used were the human N-terminal SHH, the HA (haemagglutinin)-tagged Smo and the human fulllength GLI1 which have been described before [24] , and the activated human SMO-M2 [25] .
RNase protection assay
A construct containing exon 8 spliced to exon 11 and an additional one with exon 20 spliced to exon 21 flanked by 'intronic' sequence were generated by PCR amplification (25 cycles) with the Advantage HF TM PCR kit (ClonTech Laboratories) using the PTCH2-9,10 expression construct as template. The primers were the previously used (8)-(11) forward nested, (8)-(11) reverse nested and (19)-(int21) reverse nested and a novel exon 20 forward primer (5 -TGACAGTGCTCACGCTC). PCR products were cloned into the pGEM-T vector (Promega) and the identity of the constructs was verified by sequencing (Cybergene AB). The exon 8-11 construct was linearized with SphI and NcoI (Promega), whereas the exon 20-21 construct was linearized with NotI and SalI (Promega). cRNAs were transcribed (MAXIscript TM ; Ambion, Austin, TX, U.S.A.) in the presence of 32 P-labelled UTP (Amersham Biosciences, Little Chalfont, Bucks., U.K.) with either SP6 polymerase (exon [8] [9] [10] [11] or T7 polymerase (exon [20] [21] . Total RNA (20 µg) from human testis (ClonTech Laboratories) was incubated with equal amounts of the two riboprobes and subjected to RNase protection analysis following the method of the RPA III TM kit (Ambion). Electrophoretic separation of the riboprobes and the protected fragments were performed on denaturing 8 and 10 % acrylamide/urea gels and visualized after exposure to Fuji Super RX film.
Immunofluorescence
Cells transfected with PTCH2 variants, PTCH1 and Smo expression constructs or incubated with Shh-N were permeabilized and blocked in PBS + 0.5 % Triton X-100 + 10 % normal donkey or rabbit serum for 1 h at room temperature (22
• C). Subsequently, cells were incubated in primary antibodies followed by secondary antibodies diluted in blocking solution for 1 h at room temperature. Washes were performed twice with PBS between each incubation. The following antibodies were used: Patched2 (M-20) (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) at 1:400 dilution; anti-Xpress TM mAb (monoclonal antibody; Invitrogen) at 1:100 dilution; Shh (N-19) goat antibody (Santa Cruz Biotechnology) at 1:50; rabbit PTCH-C antibody against the Cterminal 18 amino acids [9] 
Immunoprecipitation and Western blotting of PTCH1, PTCH2 and DHH
PTCH1 and/or PTCH2-transfected HEK-293 (human embryonic kidney 293) cells were lysed in PBS buffer, supplemented with 1 % Nonidet P40, protease inhibitors and 0.5 % deoxycholic acid. Immunoprecipitation was performed with anti-Xpress TM mAb (Invitrogen) or FLAG m2Ab (Stratagene) followed by Protein G plus Protein A-agarose beads and then separated on 6 % SDS/ polyacrylamide gel. Proteins were transferred on to a PVDF membrane (Millipore, Billerica, MA, U.S.A.) and probed with a 1:1000 dilution of anti-Xpress TM mAb (Invitrogen) or a 1:2000 dilution of FLAG m2Ab (Stratagene) following blocking in 10 % fat-free milk in PBS. As a secondary antibody, a conjugated horseradish peroxidase antimouse Ig was used at a 1:2000 dilution. ECL ® (enhanced chemiluminescence) detection (Pierce) was performed according to the manufacturer's instructions. To calculate the percentage of PTCH1 that is retained in the immunoprecipitate, the observed signal intensities in the cell lysate and immunoprecipitation complex were adjusted for an equivalent amount of starting material.
For DHH detection, HEK-293 cells were transfected with the DHH expression construct. Cells were lysed and processed as above. As primary antibody, a Dhh (N-19) goat antibody (Santa Cruz Biotechnology) at 1:200 dilution, and as secondary antibody, a conjugated horseradish peroxidase antigoat Ig at 1:2000 dilution, were used.
SHH internalization assay
C3H/10T1/2 cells were transfected with PTCH1 or PTCH2 antiXpress constructs. Cells were incubated 48 h after transfection, at 37
• C for 2 h with 1 nM Shh-N peptide (R&D Systems, Minneapolis, MN, U.S.A.). Cells were washed, fixed and processed for detection of PTCH1, PTCH2 and Shh-N immunofluorescence.
PTCH2 reporter gene construct
A BAC clone harbouring the PTCH2 gene was obtained from Genome System TM by custom library screening using PTCH2 primers (available on request). By primer walking, approx. 4 kb of the genomic region upstream of exon 1 was sequenced (Cybergene AB). A fragment of approx. 3.4 kb of the 5 -regulatory region, including the ATG codon in exon 1, was amplified using the Advantage HF TM PCR kit (ClonTech Laboratories) and subcloned into pGL3-Basic vector (Promega). This sequence corresponds to nucleotide positions 18 333-21 786 in the recently deposited GenBank entry (accession no. GI: 19031310), which contains the complete PTCH2 gene. This construct (PTCH2-luc) was verified by sequencing (Cybergene AB).
Transfection assays
Confluent cultures of NIH-3T3 cells were trypsinized and plated at 1:6 dilution on 24-well plates. The next day, cells were transfected with 0.2 µg of β-galactosidase control (RSV-lacZ), 0.2 µg of PTCH2-luc reporter and 0.2 µg of expression constructs, unless indicated otherwise, using 3 µl of Fugene (Roche) transfection reagent. pcDNA3.1/His B (Invitrogen) was used to reach a concentration of 1.6 µg of total DNA/well. After the cells had reached saturation density (1-2 days), the medium was changed to 0.5 % bovine calf serum and the cells were lysed 24 h later. Luciferase activity was measured using the Luciferase Assay kit (BioThema, Haninge, Sweden). Galactosidase activity was measured using Galacto-Light kit (Applied Biosystems, Foster City, CA, U.S.A.).
Confluent Ptch1 −/− cells were plated at 1:8 dilution on 24-well plates. The next day, cells were transfected with 0.2 µg of PTCH2-luc reporter, 0.2 µg of SHH-N or 0.2 µg of DHH-N and 1 µg of PTCH1/PTCH2 expression constructs, unless indicated otherwise, and 50 ng of Renilla luciferase (pRL-SV40) as transfection control. Fugene (3 µl; Roche) was used with an equal amount of DNA/well (1.45 µg) reached by using pcDNA3.1/ His B (Invitrogen). Normalized luciferase activity was determined with the dual-luciferase reporter assay system (Promega) using the Microplate Luminometer (Berthold Detection System, Pforzheim, Germany).
All experiments were repeated independently at least three times and measurements in each experiment were performed at least twice.
RESULTS
Expression analysis of PTCH2 splice variants in normal tissues
The original studies, describing the isolation of the PTCH2 cDNA, reported the presence of several splice variants [17] . Two of these are probably of significant biological importance: (a) a variant in the 3 -end region that changes the last four coding amino acids to 61 novel ones originating from the terminal 'intron', PTCH2-22 ( Figure 1 ) and (b) a variant that skips exons 9 and 10, with the open reading frame being maintained at the exon 8 to 11 junction, PTCH2-9,10 ( Figure 2 ). This region encodes the last segment of the first extracellular loop in the putative structure of PTCH1 and overlaps with the SSD motif [26] , whereas the C-terminal region is thought to have a role in repressing signalling [10] . Consequently, we initially wanted to examine the expression pattern of these variants. Using a cDNA panel (ClonTech Laboratories) as well as cerebellum (ClonTech Laboratories) and skin cDNA [9] , the region between exon 19 and the last exon, exon 22, of the PTCH2 transcripts was specifically amplified. The splice variant that had the last exon substituted by 'intronic' sequences, PTCH2-22, was abundantly expressed in all tissues examined. Strikingly, the full-length PTCH2 that includes exons 19, 20, 21 and 22 could not be observed in any tissue. However, a transcript lacking exon 21, with exon 20 joined to exon 22, could be observed in thymus, testis, ovary, leucocytes, cerebellum and skin (Figure 1 ). Most interestingly, this exon 20 to 22 splicing event changes the reading frame of exon 22, resulting in the introduction of 26 novel C-terminal residues. The relative level of expression of this exon 21-skipped transcript was lower than that of PTCH2-22. The same methodology was also used to analyse the expression pattern of the region between exons 8 and 11 in the same cDNAs ( Figure 2 ). The transcript that had these four exons spliced together, PTCH2, was present in all tissues except intestine. This tissue as well as testis, colon, cerebellum and skin contained cDNAs that had not excised intron 8, resulting in a shift of the reading frame and premature termination. Moreover, a transcript that lacked exon 9 was found in prostate, intestine and cerebellum. This skipping event, however, maintained the reading frame at the exon 8 to 10 junction. Additionally, the transcript that lacked both exons 9 and 10, PTCH2-9,10, was observed in spleen, ovary, testis, cerebellum and skin.
To obtain additional evidence by a non-PCR-based method for the presence of mRNAs encoding PTCH2-9,10 and PTCH2-22, RNase protection analysis was employed using human testis as the RNA source. Two riboprobes were generated with sizes of 207 bases for exons 8-11 and 359 bases for exons 20-21. As anticipated, protected fragments with sizes of 121 bases for exons 8-11 and 298 bases for exons 20-21 were clearly visible (Figure 3) , confirming the results from the PCR analysis.
PTCH2 variants code for proteins that localize in the cytoplasm
Since detection of endogenous PTCH2 in various cell lines by Western-blot analysis was not possible, we generated expression constructs for three of these variants, the full-length PTCH2, PTCH2-22 and PTCH2-9,10. A similar construct for PTCH1 was also generated as control. These constructs contained an anti-Xpress epitope tag at their N-terminus and were transiently transfected into COS7 cells. Additionally, the expression of endogenous PTCH2 in NIH-3T3 cells transfected with GLI1 was analysed. The localization of the corresponding proteins was determined either by indirect immunofluorescence using an antibody against the epitope tag or directly against PTCH2. The three PTCH2 variants, PTCH1 and the GLI1-induced endogenous PTCH2 localized mostly in cytoplasmic structures that may represent intracellular vesicles as has also been reported for PTCH1 [27] (Figure 4) , with no major differences among them. To verify the specificity of the antibody detecting endogenous PTCH2, epitope-tagged PTCH2-22 construct was used to transfect COS7 cells. Expressing cells were clearly detected using the antibody against PTCH2 (Figure 4b) , and similar results were also obtained after transfection of the epitope-tagged PTCH2 construct (results not shown). It has been proposed that Drosophila ptch might act indirectly to regulate smo activity, with concomitant effects on subcellular localization [28] . To test if the PTCH2 variants have the ability to alter the localization of Smo, HA-epitope-tagged Smo was transfected either alone or together with the PTCH2 isoforms as well as PTCH1. Co-transfection of Smo with either the PTCH2 variants or PTCH1 could alter the localization of Smo from being dispersed in the cytoplasm to a pattern overlapping that of the PTCH2 variants and PTCH1 ( Figure 5 ).
Heteromeric interaction between PTCH2 variants and PTCH1
Using confocal microscopy, we determined the subcellular localization of anti-Xpress-tagged PTCH2 variants and FLAGtagged PTCH1 in doubly transfected COS7 cells. All combinations of the PTCH2 variants when co-transfected with PTCH1 showed a similar co-localization pattern in the same cytoplasmic compartment (Figure 6a) . Moreover, to investigate the possible direct interaction between the PTCH2 variants and PTCH1, HEK-293 cells were also transiently transfected with these expression constructs. A complex of the PTCH2 variants and PTCH1 was detected by co-immunoprecipitation from double-transfected cells. By calculating the amount of PTCH1 present in the lysates and in the immunoprecipitated complex, we concluded that more than 20 % of input PTCH1 can be immunoprecipitated by PTCH2, suggesting that this interaction could be of physiological importance. This contrasts the < 3 % of input Smo or Ptch1 that can be immunoprecipitated by the other protein in this type of assay (see supplementary information in [27] ), arguing against its biological relevance. Therefore these results are consistent with a possible significant interaction between each of the PTCH2 variants and PTCH1 (Figures 6b-6e ).
PTCH2 variants mediate internalization of Shh-N
Ptch1 functions in the receptor-mediated endocytosis of Hh proteins [29] . The ability of Ptch1 to retrieve membrane-bound Shh forms from adjacent cells indicates that removal of Shh from the extracellular milieu is an important feature of Ptch1 function, and it is probable that internalization of Shh may be linked to signal transduction. To check whether the PTCH2 variants have the same ability, C3H/10T1/2 cells were transfected with antiXpress-tagged PTCH2 variants followed by incubation with Shh-N, the N-terminal fragment of Shh. PTCH1 was used as control and detection was performed by immunofluorescence and confocal microscopy. Incubation of PTCH2-transfected cells with the Shh-N peptide resulted in the appearance of internalized Shh-N within PTCH2-containing vesicles, as also seen with the PTCH1, whereas untransfected cells, present around transfected cells, showed no evidence of Shh-N uptake (Figure 7) . Moreover, PTCH2-22 and PTCH2-9,10 were also able to internalize Shh-N, similar to the full-length PTCH2 (results not shown).
PTCH2 promoter up-regulation by SHH signalling components
As the PTCH2 gene appears to be under the control of SHH signalling in BCCs [17] and in NIH-3T3 cells (Figure 4a) , we decided to examine this regulation in more detail. First, an approx. 3.4 kb fragment of the 5 -flanking region of the PTCH2 gene was isolated, sequenced and subcloned into the pGL3-Basic vector upstream of the firefly luciferase reporter gene (see the Materials and methods section). The presence of a GLI1-binding site (5 -TGGGTGGTC), positioned 472-463 bases upstream of the initiation ATG codon, implies a direct effect of SHH signalling in PTCH2 activation. Then we examined whether the PTCH2-luc construct, after transfection into NIH-3T3 cells, was responsive to the typical activators of the pathway, SHH-N, SMO, a mutant variant of SMO (SMO-M2) that is much more potent than the wild-type [25] and GLI1. NIH-3T3 cells have been shown to be most responsive to HH induction compared with other cell lines [30] . As shown in Figure 8 (a), all these activators of HH signalling could increase the level of expression of the reporter gene.
Differential effects of PTCH2 variants on SHH induction of PTCH2
To examine whether the PTCH2 splice variants may influence SHH-N up-regulation of the PTCH2 promoter, co-transfection analysis was also performed. SHH-N induction was apparently inhibited by the PTCH2-22 variant in a dose-dependent manner. On the other hand, for PTCH2 and PTCH2-9,10, increasing the amounts of expression construct from 0.2 to 1 µg did not result in a similar pattern of inhibition (Figure 8b ). Thus inclusion of exons 9 and 10 and exclusion of exon 22/inclusion of 'intron' 21 sequences are necessary for dose-dependent inhibition. Moreover, the observed PTCH1 inhibition of the SHH-N induction was always found to be stronger when compared with that of PTCH2-22.
In contrast with these findings, SMO-M2 induction could only be inhibited by PTCH1, with the three PTCH2 splice variants apparently lacking that capacity. Increasing the amounts of the PTCH2/PTCH1 expression constructs did not substantially alter the observed pattern (Figure 8c ).
Differential reconstitution of SHH transcriptional response by PTCH1/PTCH2 variants
To analyse the effects of the PTCH2 variants and PTCH1 on HH signalling in a different cellular context, we also used embryonic fibroblasts derived from Ptch1 −/− mouse embryos. These cells have widespread activation of Shh target genes including Gli1 [30] . As described by Taipale et al. [30] , Ptch2 activity is not detected in Ptch1 −/− cells, as Shh transfection of these cells could not further increase target gene activation. As anticipated, the PTCH2 promoter construct was found to be highly active in these cells (Figure 9a ). This promoter activity could be strongly inhibited by PTCH1. Only the PTCH2-22 variant was capable of inhibiting the PTCH2 promoter, but still not to the same extent as PTCH1. Additionally, the strong PTCH1 inhibition was already detected with the least amount of expression construct ( Figure 9b ) and a similar pattern was also observed with the PTCH2 variants (results not shown). Most interestingly, the PTCH1/PTCH2-22 inhibition was relieved by SHH for PTCH1 but not for PTCH2-22, implying that only PTCH1 can reconstitute a ligand-dependent transcriptional response (Figure 9a) .
Differential reconstitution of DHH transcriptional response by the PTCH2 variants
Ptch2 is known to be expressed in spermatocytes, where it may mediate the function of Dhh by regulating Gli1 and Gli3 [21, 31, 32] . Dhh-deficient mice are sterile because of lack of mature sperm [33] . Interestingly, in testicular germ cell tumours, deletions of the chromosomal region 1p32-36 [34] , the locus of the PTCH2 gene, have been observed indicating a possible role as a tumour suppressor in this setting. Our results have shown that PTCH2 is not a direct mediator of SHH signalling as is PTCH1, thus opening the possibility that PTCH2 may be an effective mediator of DHH signalling. To test this hypothesis, we generated a human DHH expression construct (see the Materials and methods section) and confirmed the synthesis of the protein by Western blotting (Figure 10 ). Using the Ptch1 −/− cells, we attempted to reconstitute a transcriptional response by now employing DHH instead of SHH. PTCH2 and PTCH2-9,10 were found to be inactive in this assay. However, PTCH2-22-transfected cells did show a significant up-regulation in response to DHH exposure, albeit not to the same extent as PTCH1 (Figure 11 ).
DISCUSSION
In this study, we describe the analysis of gene products generated by the human PTCH2 gene. In agreement with the realization that alternative splicing increases the complexity of the proteome [35] , this process was found to influence PTCH2 expression in all tissues examined. Two previously non-detected, variant PTCH2 transcripts were also identified highlighting the diverse complexity in the C-terminal region and the SSD domain, segments thought to have a role in mediating signalling. The functional significance of the splice products that either lack the last exon (PTCH2-22) or exons 9 and 10 (PTCH2-9,10) was examined in more detail.
Indirect immunofluorescence revealed that the localization of these splice variants is in the cytoplasm. However, direct detection of endogenous PTCH2 was only possible in NIH-3T3 cells transfected with the GLI1 expression construct, implying that signalling up-regulates PTCH2. It was shown that the PTCH2 mRNA isoforms as well as the full-length PTCH2 mRNA code for proteins that are able to change Smo localization from being dispersed in the cytoplasm to a more concentrated region near the nucleus where the PTCH2 variants are localized. Similar results were also observed with PTCH1. The mechanism of inhibition of SMO signalling by PTCH1 is not exactly known. A recent study has shown that Ptch1 inhibits Smo only when both are localized in the same cellular compartment. Shh-induced dissociation allows Smo to signal after it is sorted from the Ptch1/Shh complexes in the late endocytic pathway [36] . In an additional study, it was proposed that Ptch1 might inhibit Smo by forcing it to a subcellular compartment containing either small molecule antagonists or lacking small molecule agonists [37] . The fact that several studies in different systems have observed localization changes for SMO and PTCH1 on ligand binding shows the importance of this feature in HH signalling. However, we were not able to detect major differences among the PTCH2 variants in localization/interaction with Smo, even though alterations in the SSD domain have been implicated to influence Smo signalling [14, 15] . Additionally, we could also show co-localization and heteromeric interaction between the PTCH2 variants and PTCH1 in double-transfected cells. The physiological role of this interaction is not yet known. In chick embryo [38] , mouse teeth and hair bud [39, 40] , a close correlation between cellular sites of high Ptch2 expression and Hh signalling has been shown. Therefore it is conceivable that in some cellular contexts, PTCH1/ PTCH2 interactions may be critical for an optimal biological response. Moreover, we could show that the PTCH2 variants have the same ability as PTCH1 to internalize Shh-N from the surrounding extracellular environment. PTCH1 is known to interact with caveolin, which is important in endocytosis and trafficking [41] , and is also thought to act as a transporter because of its structural similarity to small molecule transporter proteins [27] . Thus PTCH1 and PTCH2 may couple both HH sequestration and the release of SMO inhibition with the late endosomal transport.
Using functional assays, we also examined whether the PTCH2 splice variants and PTCH1 could inhibit SHH induction. Results revealed dramatic differences in the extent of the inhibition observed for each of these molecules. The strongest inhibitor was found to be PTCH1. Among the PTCH2 variants, only PTCH2-22 could inhibit in a dose-dependent manner, approaching at the highest dose the extent of inhibition observed with PTCH1. These findings imply that inclusion of exons 9 and 10 as well as the presence of an alternative C-terminus is essential for maximal repressor function of PTCH2. Results pointing to the same differences between the PTCH2 variants and PTCH1 were also observed using Ptch1 −/− cells. In addition, the fact that the PTCH2 variants could not inhibit SMO-M2 activity, whereas PTCH1 did, albeit to a lower extent than the observed inhibition of SHH activation, further highlight the functional differences between these proteins. This SMO-M2 mutant, identified in sporadic BCCs, carries a Trp 535 to Leu substitution in the seventh transmembrane domain, which makes the protein much more potent than the wild-type [25] . This is in agreement with our findings that PTCH1 is a stronger inhibitor of SHH when compared with SMO-M2 activation of the PTCH2 promoter. Evidence has been presented that Ptch1 may inhibit Smo by a nonstoichiometric, catalytic mechanism making this inhibition less dependent on the dose of the Ptch1 protein [27, 42] , and this is consistent with our observations that decreasing the amount of PTCH1 did not change the inhibition pattern. It is probable that the generation of chimaeric constructs with interchanged PTCH1/ PTCH2 domains may help delineate the PTCH1 segments responsible for repressing SMO activity.
In agreement with the observed intrinsic differences in PTCH2/PTCH1 inhibition of SHH signalling in NIH-3T3 cells, PTCH2 could not compensate for the loss of PTCH1 in BCCs [17] . This is consistent with the fact that Ptch1 −/− mice die at an early embryonic stage [43, 44] in spite of Ptch2 expression [45] . However, it is still conceivable and more probable that in vivo PTCH1 and PTCH2 are expressed at different time points and in different cell types and thus cannot compensate for each other. Such phenomena have been seen when Gli1 cDNA was knocked into the Gli2 locus and rescued all the Shh signalling defects observed in the Gli2 −/− mice [7] . This is despite the fact that Gli2 −/− mice die at birth, whereas Gli1 −/− mice are phenotypically normal [46] .
As Dhh −/− mice have testicular abnormalities [34] and PTCH2 is expressed in testis [21] , we also examined the efficiency of the PTCH2 splice variants in mediating a DHH transcriptional response. PTCH2-22 had this capacity, whereas the other variants could not mediate any response. Thus PTCH2-22 appears to be the biologically more significant isoform.
In summary, we have shown that the PTCH2 promoter is under the control of the HH signalling pathway supporting a functional role of PTCH2 in the pathway. Additionally, we demonstrated that in an appropriate cell context the PTCH2 splice variants have distinct functional properties when compared with PTCH1, with PTCH2-22 consistently mediating a stronger response when compared with the other variants. The differences between PTCH2 and PTCH1 appear to reside mainly downstream of the SHH internalization step. Only the PTCH2-22 variant reconstitutes DHH-dependent-signalling activation, whereas none of these variants is able to reconstitute a SHH response. However, this capacity of PTCH2-22 was much weaker than that of PTCH1. Thus the expressions of splice variants of the HH receptor PTCH2 may be considered to represent a mechanism that fine tunes signalling in various cellular environments. Differences in the capacity to influence HH signalling by these two kinds of receptors can explain the inability of PTCH2 to substitute the function of mutated or deleted PTCH1 in tumours arising from disruption of this pathway. Therefore PTCH2 may have a more restricted role when compared with PTCH1, not excluding the possibility that PTCH2 could couple HH signalling to as yet unknown downstream effectors.
